Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.

Yolanda Braun-MoscoviciMarielle KaplanMaya BraunDoron MarkovitsSamy GiryesKohava ToledanoYonit TavorKatya DolnikovAlexandra Balbir-Gurman

Published in: Annals of the rheumatic diseases (2021)

The vast majority of patients with IRD developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

Keyphrases

sars cov
disease activity
immune response
rheumatoid arthritis
systemic lupus erythematosus
respiratory syndrome coronavirus
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
binding protein
computed tomography
coronavirus disease